Open main menu
Home
Random
Recent changes
Special pages
Community portal
Preferences
About Wikipedia
Disclaimers
Incubator escapee wiki
Search
User menu
Talk
Dark mode
Contributions
Create account
Log in
Editing
Essential tremor
(section)
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
=== Additional procedures === ====Ultrasound==== [[File:MRI-guided HIFU, essential tremor, 10-14 135, pointed.png|thumb|Frontal MRI four days after MRgFUS (MRI-guided high-intensity focused ultrasound): Left ventral intermediate nucleus (Vim) thalamotomy. 79-year-old man with essential tremor.]] Additionally, [[MRI]]-guided [[high-intensity focused ultrasound]] is a nonsurgical treatment option for people with essential tremor who are medication refractory.<ref name=pmid28503363>{{cite journal | vauthors = Rohani M, Fasano A | title = Focused Ultrasound for Essential Tremor: Review of the Evidence and Discussion of Current Hurdles | journal = Tremor and Other Hyperkinetic Movements | volume = 7 | pages = 462 | year = 2017 | pmid = 28503363 | pmc = 5425801 | doi = 10.7916/D8Z89JN1 | doi-broken-date = 25 February 2025 }}</ref><ref name=FDA2016>{{cite press release |title=FDA approves first MRI-guided focused ultrasound device to treat essential tremor |url=https://www.fda.gov/news-events/press-announcements/fda-approves-first-mri-guided-focused-ultrasound-device-treat-essential-tremor |archive-url=https://web.archive.org/web/20201108091524/https://www.fda.gov/news-events/press-announcements/fda-approves-first-mri-guided-focused-ultrasound-device-treat-essential-tremor |url-status=dead |archive-date=November 8, 2020 |publisher=FDA |date=24 March 2020 }}</ref> MRI-guided high-intensity focused ultrasound does not achieve healing, but can improve the quality of life by reducing the tremor manifestation.<ref name=FDA2016 /><ref>{{cite journal|date=2023|volume=9|issue=1|pages=17β20|doi=10.1515/cdbme-2023-1005|vauthors=Aharonson V, Postema M, Gebbie R, Van Der Merwe J, Schlesinger I|title=Sobel edge detection for quantifying the effectiveness of focused ultrasound thalamotomy for tremor relief|journal=Current Directions in Biomedical Engineering|doi-access=free}}</ref> While its long-term effects are not yet established, the improvement in tremor score from baseline was durable at 1 year and 2 years following the treatment.<ref name=pmid29265546>{{cite journal | vauthors = Chang JW, Park CK, Lipsman N, Schwartz ML, Ghanouni P, Henderson JM, Gwinn R, Witt J, Tierney TS, Cosgrove GR, Shah BB, Abe K, Taira T, Lozano AM, Eisenberg HM, Fishman PS, Elias WJ | title = A prospective trial of magnetic resonance-guided focused ultrasound thalamotomy for essential tremor: Results at the 2-year follow-up | journal = Annals of Neurology | volume = 83 | issue = 1 | pages = 107β114 | date = January 2018 | pmid = 29265546 | doi = 10.1002/ana.25126 | s2cid = 4437809 }}</ref> To date, reported adverse events and side effects have been mild to moderate. Possible adverse events include gait difficulties, balance disturbances, [[paresthesia]]s, [[headache]], skin burns with ulcerations, skin retraction, scars, and blood clots.<ref name=pmid28503363/><ref name="FDA2016" /><ref name="Hedera2017">{{cite journal | vauthors = Hedera P | title = Emerging strategies in the management of essential tremor | journal = Therapeutic Advances in Neurological Disorders | volume = 10 | issue = 2 | pages = 137β148 | date = February 2017 | pmid = 28382111 | pmc = 5367648 | doi = 10.1177/1756285616679123 | type = Review }}</ref> This procedure is contraindicated in pregnant women, persons who have non-MRI compatible implanted metallic devices, allergy to MR contrast agents, cerebrovascular disease, abnormal bleeding, hemorrhage and/or blood clotting disorders, advanced kidney disease or on dialysis, heart conditions, severe hypertension, and ethanol or substance abuse, among others.<ref name="FDA2016" /> The US Food and Drug Administration ([[Food and Drug Administration|FDA]]) approved Insightec's Exablate Neuro system to treat essential tremor in 2016.<ref name="FDA2016" /> ==== Deep Brain Stimulation (DBS) ==== [[File:Adaptive Deep Brain Stimulation.png|thumb|Illustration of the placement of electrodes and stimulator of Deep Brain Stimulation surgical treatment.]] Another invasive surgical treatment of essential tremor is deep brain stimulation (DBS). DBS is a surgical procedure that involves the placement of a permanent electrode with 4-8 contacts within the brain with connecting wires connected to a pulse stimulator implanted near the patient's collarbone.<ref name=":1" /> In the treatment of tremor, the electrodes are placed in the ventral intermediate nucleus (Vim) of the thalamus. The pulse stimulator delivers constant electrical pulses to the target area, which interfere with activity of the target area, which has been shown to improve tremor symptoms.<ref>{{cite journal | vauthors = Singh M, Agrawal M | title = Deep Brain Stimulation for Tremor and Dystonia | journal = Neurology India | volume = 68 | issue = Supplement | pages = S187βS195 | date = 2020 | pmid = 33318349 | doi = 10.4103/0028-3886.302472 | doi-access = free }}</ref> At one year following the surgical intervention with DBS, patients showed 66% improvement and 48% improvement at 10 years.<ref name=":8" /> DBS is considered an effective surgical treatment of ET, but there are associated side effects and complications that have been reported with DBS in clinical trials, including imbalance or gait instability, dystonia, paresthesia, hemorrhage.<ref name=":7" />
Edit summary
(Briefly describe your changes)
By publishing changes, you agree to the
Terms of Use
, and you irrevocably agree to release your contribution under the
CC BY-SA 4.0 License
and the
GFDL
. You agree that a hyperlink or URL is sufficient attribution under the Creative Commons license.
Cancel
Editing help
(opens in new window)